Key Highlights
- Revolution Medicines (NASDAQ:RVMD) recorded USD 197.6 million of net product Revenue in the third quarter of 2026, its first revenue from product sales, after FDA approval of RASONQUE in August.
- The net loss was USD 407.5 million, or USD 1.90 per share, compared with USD 305.2 million, or USD 1.61, a year earlier, as spending rose with the launch.
- Research and development expense climbed 59% to USD 417.1 million, while selling, general and administrative expense rose 191% to USD 153.3 million.
- Cash, cash equivalents and marketable securities totaled USD 3.7 billion on September 30, 2026, up from USD 2.0 billion at the end of 2025.
RASONQUE Launch Delivers First Product Revenue
Revolution Medicines (NASDAQ:RVMD) filed its Quarterly Report on November 4, 2026, covering the three months ended September 30. In August 2026 the FDA approved RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent therapy. Net product revenue was USD 197.6 million in the quarter and nil in the prior-year period, and cost of sales was only USD 0.3 million. Revenue is concentrated: two customers accounted for 71% and 28% of net product revenue. The company began capitalizing inventory for the drug at approval, so earlier Manufacturing costs were expensed as research and development.
Spending Surge Keeps the Quarterly Loss at USD 407.5 Million
The company develops RAS(ON) inhibitors, a class aimed at cancers driven by RAS mutations, with zoldonrasib and elironrasib among its other candidates. The loss from operations widened to USD 373.1 million from USD 315.3 million. Research and Development rose to USD 417.1 million on higher clinical trial and manufacturing costs, including pre-launch materials expensed before approval. Selling, general and administrative expense reached USD 153.3 million, driven by commercial expenses, headcount and stock compensation. Non-operating items added pressure: interest expense rose to USD 33.8 million, and a USD 40.7 million increase in the Warrant liability, tied to a higher share price, was charged. Interest income of USD 37.8 million partly offset them. For nine months, the net loss was USD 1.51 billion, or USD 7.24 per share (calculated from USD 1,505.6 million).
USD 3.7 Billion of Liquidity, a New Loan Draw and Royalty Choices
Cash, cash equivalents and marketable securities stood at USD 3.7 billion, which management believes funds planned operations for at least 12 months. In October 2026, following approval, Revolution Medicines (NASDAQ:RVMD) drew a first USD 250.0 million Tranche of its term loan Facility and paid a USD 5.0 million upfront fee. It also elected not to take a third tranche from Royalty Pharma that would have added up to USD 250.0 million in exchange for further royalties. Nine-month at-the-market stock sales raised USD 271.9 million gross from 2,070,899 shares. Also in October, it signed a clinical trial collaboration with Bristol-Myers Squibb on a bispecific antibody. Risks include launch pace, pricing and reimbursement, supply, and spending that management expects to keep rising.
Where Things Stand
The first-sales figure follows the August FDA approval of RASONQUE. Revolution Medicines (NASDAQ:RVMD) booked USD 197.6 million in the part of the quarter after approval, though two customers made up 99% of it (calculated). The filing does not say how much was initial stocking, so it is not yet a measure of steady demand. The loss still widened to USD 407.5 million as research and commercial costs rose. Next markers are quarterly sales trends in the fourth quarter, the customer mix, expense growth, the drawn term loan and progress in the broader RAS(ON) pipeline.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...